0.00Open0.05Pre Close0 Volume1.01K Open Interest3.00Strike Price0.00Turnover546.38%IV192.99%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1607Delta0.3043Gamma20.82Leverage Ratio-0.0133Theta0.0000Rho3.35Eff Leverage0.0004Vega
Immunic Stock Discussion
Immunic Highlights 2024 Accomplishments and Upcoming Milestones
Tuesday, 7th January at 6:30 am
– Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April –
– Reported Positive Outcome from Interim Analysis of Ongoing, Twin Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Both Trials on Track to Be Completed in 2026 –
– Strengthened Management Team and Board of Directors with Key Hir...
Anything Important?
No comment yet